Compare BVS & EMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVS | EMD |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.1M | 578.4M |
| IPO Year | 2016 | N/A |
| Metric | BVS | EMD |
|---|---|---|
| Price | $10.49 | $10.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 440.5K | 273.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.25% |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.81 | $9.00 |
| 52 Week High | $10.58 | $11.30 |
| Indicator | BVS | EMD |
|---|---|---|
| Relative Strength Index (RSI) | 72.59 | 64.11 |
| Support Level | $8.43 | $10.15 |
| Resistance Level | N/A | $10.96 |
| Average True Range (ATR) | 0.36 | 0.22 |
| MACD | 0.14 | 0.12 |
| Stochastic Oscillator | 91.23 | 95.16 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.